Screening of Biomarkers and Related Mechanisms for RIX
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
A large number of patients undergoing radiotherapy and chemotherapy are suffering from dry mouth. Due to reduced saliva secretion, patients may experience symptoms such as difficulty chewing and swallowing. In severe cases, they may also experience pain and burning sensation in the oral mucosa, decreased taste, ulcers, which seriously affect the quality of life of patients. However, radiation-induced dry mouth lacks early objective predictive indicators (molecular biomarkers) and the mechanism is unclear. Only when patients experience clinical symptoms will symptomatic treatment be taken to alleviate them. Therefore, elucidating the mechanism of radiation-induced dry mouth syndrome (RIX) and achieving early prediction, detection, and intervention of RIX are crucial in improving the prognosis and quality of life of radiotherapy patients. It is urgent to seek early and precise detection targets in clinical practice to predict dry mouth caused by irreversible damage to salivary gland tissue. This study aims to collect blood samples from patients with severe dry mouth before and after radiotherapy and chemotherapy in clinical practice. Multiple omics techniques will be used to search for predictive molecular biomarkers for RIX, construct a predictive model, and verify the sensitivity and specificity of the biomarkers. The goal is to predict the occurrence of RIX early in clinical practice, intervene in advance, greatly improve the prognosis of radiotherapy and chemotherapy patients, and enhance their quality of life.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie rak głowy lub szyi
- •Planowana radioterapia lub radioterapia w połączeniu z chemioterapią, immunoterapią lub terapią celowaną
- •Wiek co najmniej 18 lat
- •Pełne zrozumienie celu badania i dobrowolna zgoda na uczestnictwo
✗ Disqualifies
- •Nowotwór przerzutowy (rozprzestrzeniający się na inne części ciała)
- •Wcześniejsza radioterapia głowy lub szyi
- •Poważna suchość jamy ustnej przed radioterapią
- •Zaawansowana niewydolność serca, nerek lub wątroby
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- September 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (4)
The First Affiliated Hospital of Nanjing Medical University
Nanjing, China
Affiliated Jinling Hospital, Medical School of Nanjing University
Nanjing, China
Jiangsu Cancer Hospital
Nanjing, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
Trial contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.